Literature DB >> 12752127

Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities.

I Zalaudek1, M Horn, E Richtig, S Hödl, H Kerl, J Smolle.   

Abstract

BACKGROUND: Melanoma in situ (MIS) occurs on various body sites, in various age groups, and is managed by a variety of treatment modalities. Despite early treatment, recurrences may be encountered.
OBJECTIVES: To evaluate the influence of sex, age, body site and treatment modalities on recurrence rate in MIS. Methods Histologically confirmed cases of MIS from our dermatopathological database (n = 1351) from 1990 to 2000 were statistically analysed with respect to epidemiological characteristics, treatment modalities and outcome. Treatment modalities of the included MIS were evaluated by searching for data in the medical records and histopathological data sheets.
RESULTS: There was a predominance of female patients (60.8%), and of involvement of the head and neck (53.4%). Total excision was performed in 95.9% of all patients; the remainder received cryotherapy, laser therapy or radiotherapy. In 265 patients, no data on definitive treatment were available. Alternatives to total excision were particularly performed in patients with advanced age and with lesions localized on the face. The mean +/- SD 5-year recurrence rate was 6.8 +/- 1.3% for surgically removed lesions, but was 31.3 +/- 8.5% for lesions treated by other modalities (log rank test: P < 0.0001). In a multivariate approach, mode of therapy and site of involvement, but not age, were significant prognostic variables (Cox proportional hazard model: P < 0.01).
CONCLUSIONS: In MIS, treatment modalities other than surgical excision may be used in certain situations, but carry a significantly increased risk of local recurrence.

Entities:  

Mesh:

Year:  2003        PMID: 12752127     DOI: 10.1046/j.1365-2133.2003.05155.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Lentigo maligna and lentigo maligna melanoma: contemporary issues in diagnosis and management.

Authors:  Karen L Connolly; Kishwer S Nehal; Klaus J Busam
Journal:  Melanoma Manag       Date:  2015-05-18

Review 3.  Radiation therapy for cutaneous melanoma.

Authors:  Christopher A Barker; Nancy Y Lee
Journal:  Dermatol Clin       Date:  2012-06-07       Impact factor: 3.478

Review 4.  Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management.

Authors:  A Ireland; M Millward; R Pearce; M Lee; M Ziman
Journal:  Clin Exp Metastasis       Date:  2011-02-11       Impact factor: 5.150

5.  In Situ Melanoma of the Gingiva Associated with Dense Inflammation and Pigment Deposition: A Potential Diagnostic Pitfall in Evaluating Stromal Invasion.

Authors:  Bruno Tavares Sedassari; Nelise Alexandre da Silva Lascane; André Luis Santana de Freitas; Mário Cláudio Mautoni; Mirian Nacagami Sotto; Marina Helena Cury Gallottini; Suzana Cantanhede Orsini Machado de Sousa; Décio Dos Santos Pinto
Journal:  Head Neck Pathol       Date:  2016-05-13

6.  Lentigo maligna melanoma with a history of cosmetic treatment: Prevalence, surgical outcomes and considerations.

Authors:  Brian P Hibler; Karen L Connolly; Erica H Lee; Anthony M Rossi; Kishwer S Nehal
Journal:  Lasers Surg Med       Date:  2017-05-29       Impact factor: 4.025

Review 7.  [Skin tumours of the facial area].

Authors:  M Braun-Falco
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

8.  Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma.

Authors:  A J Page; A Li; A Hestley; D Murray; G W Carlson; K A Delman
Journal:  Int J Surg Oncol       Date:  2012-03-18

9.  Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review.

Authors:  Alexandra Hendrickx; Antonio Cozzio; Ludwig Plasswilm; Cédric M Panje
Journal:  Radiat Oncol       Date:  2020-07-14       Impact factor: 3.481

10.  Ten-year Follow-up Study of Grenz Ray Treatment for Lentigo Maligna and Early Lentigo Maligna Melanoma.

Authors:  Iara R T Drakensjö; Einar Rosen; Margareta Frohm Nilsson; Ada Girnita
Journal:  Acta Derm Venereol       Date:  2020-10-06       Impact factor: 3.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.